Pharming B.V.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Pharming B.V.
Live alerts from global media, monitored by Business Radar
2025-02-06 (finanznachrichten.de)
Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024
Read more
2025-02-06 (finanznachrichten.de)
Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024
Read more
2025-02-06 (finanznachrichten.de)
Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024
Read more
2024-10-24 (deaandeelhouder.nl)
Sijmen de Vries stops at Pharming
During the third quarter results, Pharming announced that CEO Sijmen de Vries will step down as figurehead and CEO of the company. De Vries is now 65 years old and has been active as CEO of Pharming for 16 years this week. De Vries: "I have informed the Board of Directors that, after 16 years at the helm of Pharming, I
Read more
2024-10-24 (iex.nl)
CEO De Vries stops at Pharming
Sijmen de Vries will step down as CEO at Pharming after sixteen years to make way for a successor. The company announced this on Thursday with the third quarter figures, which showed steady growth.
Read more
2024-10-24 (welingelichtekringen.nl)
Unilever rises in AEX, Pharming drops after CEO departure
AMSTERDAM (ANP) - Unilever was among the strongest risers in the AEX index on Thursday. The food group managed to sell more products for the fourth quarter in a row, despite further price...
Read more
2024-08-01 (iex.nl)
IEX closing call on Thursday, August 1, 2024
Weak US industry data is pushing shares in Amsterdam, Europe and the US deeply down. Bond investors can laugh, just like investors in the figures AMG, Fagron and Aperam.
Read more
2024-08-01 (deaandeelhouder.nl)
Pharming: Ruconest is going fast
Pharming shows strong growth in the second quarter at the ancient Ruconest. Ruconest continues to amaze; another hundred patients were added, which resulted in a 23% increase in turnover.
Read more
2024-07-18 (globenewswire.com)
Pharming Group to report second quarter and first half 2024 financial results on August 1
Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary...
Read more
2024-07-18 (globenewswire.com)
Pharming Group to report second quarter and first half 2024 financial results on August 1
Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary...
Read more
2024-06-02 (rtl.nl)
'Good sales of Pharming in the US'
Pharming saw sales of star drug Ruconest in the United States pick up "well" in the second quarter of the year, KBC said, raising its recommendation on the share from hold to accumulate.
Read more
2024-05-31 (iex.nl)
Setback at EMA results in loss of time for Pharming
Pharming Group has experienced a delay of approximately 18 months in the approval process of leniolisib for the treatment of APDS by the EMA, the European Medicines Agency.
Read more